Industry News
Biotechnology Industry News

Chutes & Ladders—After 9 years at Merck, Roy Baynes follows Roger Perlmutter to Eikon
Chutes & Ladders—After 9 years at Merck, Roy Baynes follows Roger Perlmutter to Eikon mbayer Thu, 03/24/2022 - 14:03
Ligand takes a crack at a SPAC to buoy spun-off antibody discovery business
Ligand takes a crack at a SPAC to buoy spun-off antibody discovery business mbayer Thu, 03/24/2022 - 11:12
Homology gets clarity on how to resolve pheNIX gene therapy hold
Homology gets clarity on how to resolve pheNIX gene therapy hold aarmstrong Thu, 03/24/2022 - 10:22
From whiteboard to white coat: Roivant Social Ventures teams up with San Diego drug discovery center to bolster diversity in biopharma
From whiteboard to white coat: Roivant Social Ventures teams up with San Diego drug discovery center to bolster diversity in biopharma mbayer Thu, 03/24/2022 - 09:29
Pfizer grabs another breakthrough tag for RSV shot in older adults
Pfizer grabs another breakthrough tag for RSV shot in older adults aarmstrong Thu, 03/24/2022 - 09:04
Hookipa CEO waives 50% of salary in bet on brighter days
Hookipa CEO waives 50% of salary in bet on brighter days ntaylor Thu, 03/24/2022 - 08:34
Orion staff brace for layoffs, program terminations after cancer and pain emerge as R&D stars
Orion staff brace for layoffs, program terminations after cancer and pain emerge as R&D stars ntaylor Thu, 03/24/2022 - 06:57
Could a simple dietary supplement treat Alzheimer’s?
Could a simple dietary supplement treat Alzheimer's? mbayer Wed, 03/23/2022 - 14:23
Celsius turns up the heat with lead drug selection, $83M financing
Celsius turns up the heat with lead drug selection, $83M financing ssorensen Wed, 03/23/2022 - 13:46
Another Eylea rival struggles in phase 2, this time fielded by Ribomic
Another Eylea rival struggles in phase 2, this time fielded by Ribomic aarmstrong Wed, 03/23/2022 - 12:40
How creative chemistry and collaboration synthesized a better drug strategy for Enterin
How creative chemistry and collaboration synthesized a better drug strategy for Enterin mwen Wed, 03/23/2022 - 10:49
After ‘masterful’ development of Keytruda, Merck’s CMO follows Roger Perlmutter to Eikon
After ‘masterful’ development of Keytruda, Merck’s CMO follows Roger Perlmutter to Eikon aarmstrong Wed, 03/23/2022 - 10:23
2seventy bio’s honeymoon phase is over as job cuts hit 6% of staff
2seventy bio's honeymoon phase is over as job cuts hit 6% of staff mbayer Wed, 03/23/2022 - 10:08
Former Pfizer staffers counter pharma giant’s ‘belated and ill-founded’ trade secrets case
Former Pfizer staffers counter pharma giant's ‘belated and ill-founded’ trade secrets case aarmstrong Wed, 03/23/2022 - 09:50
Pfizer’s $7B bet delivers phase 3 success, advancing bid to establish new drug in ulcerative colitis Arena
Pfizer's $7B bet delivers phase 3 success, advancing bid to establish new drug in ulcerative colitis Arena ntaylor Wed, 03/23/2022 - 08:30
Despite 0% response rate, 4D hits primary endpoint in Keytruda combo trial, sending stock skyward
Despite 0% response rate, 4D hits primary endpoint in Keytruda combo trial, sending stock skyward ntaylor Wed, 03/23/2022 - 07:08
LifeMine locks down $70M ‘dream scenario’ fungi partnership with GSK—and a fundraising, too
LifeMine locks down $70M 'dream scenario' fungi partnership with GSK—and a fundraising, too aarmstrong Tue, 03/22/2022 - 14:27
NIH-backed HDT Bio sues Indian partner for $950M, alleging it stole trade secrets
NIH-backed HDT Bio sues Indian partner for $950M, alleging it stole trade secrets mbayer Tue, 03/22/2022 - 13:28
Ocelot Bio gets a cool $36M series A and a new CEO to boot
Ocelot Bio gets a cool $36M series A and a new CEO to boot ssorensen Tue, 03/22/2022 - 11:29
ORIC walks away from lead cancer resistance program after lackluster phase 1b data
ORIC walks away from lead cancer resistance program after lackluster phase 1b data aarmstrong Tue, 03/22/2022 - 09:58

